Owlstone Medical has secured an award of up to £39.3m million from the Advanced Research Projects Agency for Health (ARPA-H) to support the development of next-generation breath and urine-based cancer diagnostics. The Cambridge-based company, behind the ‘Breath Biopsy’ platform which aims to diagnose disease, will lead the POSEIDON (Platform Optimizing SynBio for Early Intervention and … Continue reading Owlstone Medical awarded £39m to detect cancer early in US